Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ENSG00000297752 refers to a novel, uncharacterized long noncoding RNA transcript, antisense to the NOMO3 gene. It is detected in genomic surveys and lncRNA catalogs, but does not encode a protein and does not show established biological function, disease relevance, or druggability. Antisense lncRNAs can theoretically regulate their sense partners via transcriptional interference, RNA-RNA interactions, or epigenetic modification, but no such roles or clinical significance for ENSG00000297752 have been described in the literature or major databases. This entry should not be considered a classical pharmacological, diagnostic, or therapeutic target. If structured information for therapeutic target pipelines is needed, this lncRNA should be flagged as not a conventional therapeutic target and likely out-of-scope for drug development or biomarker use, based on publicly available data as of September 2025.
Not applicable; there are no therapeutics targeting this RNA
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Novel transcript, antisense to NOMO3 (ENSG00000297752).